Effects of a Dietary Supplement Containing L-Arabinose and Trivalent Patented Food-source of Chromium on Blood Glucose and Insulin

Pre-diabetes Clinical Trial

— L-Arabinose  

Official title:

A Combination of L-Arabinose and Chromium Lowers Circulating Glucose and Insulin Levels After Acute Oral Sucrose Challenge

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01107431
• Other study ID #: Pharmachem 40-47
• Status: Completed
• Phase: N/A
• First received: April 19, 2010
• Last updated: May 11, 2011
• Start date: December 2008
• Est. completion date: December 2009

Study information

• Verified date: May 2011
• Source: Integrative Health Technologies, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This study was designed to examine changes in capillary blood glucose and venous insulin levels after a 70 gram oral sucrose challenge with and without simultaneous consumption of a dietary supplement containing L-Arabinose and a patented version of chromium (LA-Cr).

Description:

This study concluded that consumption of the LA-Cr supplement in conjunction with a 70-gram sucrose challenge led to a significant reduction of capillary blood glucose and venous insulin as compared to the sucrose challenge without the LA-Cr supplement. This finding may provide an important tool to reduce the adverse effects associated with elevated glucose and insulin levels.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: December 2009
• Est. primary completion date: December 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All study subjects were required to contact their family physician to ensure they had no medical conditions that would preclude their participation.

Exclusion Criteria:

• Diabetics, and

• Those not approved by their physicians.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Pre-diabetes

Intervention

Dietary Supplement:
• L-Arabinose and Chromium
Consumed 70 grams of sucrose simultaneously taking a dietary supplement
• Sucrose without dietary Supplement
Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium

Locations

Country	Name	City	State
United States	Integrative Health Technologies	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Integrative Health Technologies, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fasting Blood Glucose	Finger-stick glucose measurements taken every 15 or 30 minutes after taking a 70 gram sucrose challenge with and without the dietary supplement	Every 15 to 30 minutes	No
Secondary	Fasting Blood Insulin Levels	A venipuncture blood test taken 30, 60, 90 and 120 minutes after taking a 70 gram sucrose challenge with and without taking the dietary supplement	Every 30 minutes	No